The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear ...
Two Saudi Arabian agencies signed on with Vertex Pharmaceuticals to help boost the country’s gene therapy production capabilities during the first CPhI (Convention on Pharmaceutical Ingredients) event ...
Vertex Pharmaceuticals recently announced that the FDA has granted Breakthrough Therapy Designation to povetacicept for IgA nephropathy, along with key clinical advancements in its kidney disease ...
Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer ...
Boston-based Vertex reported revenue of $3.08 billion, an 11 percent gain from one year ago. That was ahead of analysts’ ...
Vertex Pharmaceuticals Inc.’s acquisition of Alpine Immune Sciences Inc. makes strategic sense and will bolster the company’s rare-disease franchise by adding a potentially billion-dollar product, ...
For Vertex Pharmaceuticals, the first quarter of 2025 brought good news and bad news. On the bright side, early momentum for newly launched cystic fibrosis (CF) med Alyftrek and pain treatment ...
Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.
Vertex Pharmaceuticals is offering Enlaza Therapeutics more than $2 billion in biobucks through a multitarget drug discovery deal aiming to create new T-cell engagers and small-format drug conjugates.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback